Clinical Trials Logo

Mantle Cell Lymphoma clinical trials

View clinical trials related to Mantle Cell Lymphoma.

Filter by:
  • Recruiting  
  • « Prev · Page 10

NCT ID: NCT02851589 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Start date: July 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.

NCT ID: NCT02819583 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Start date: October 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.

NCT ID: NCT02267590 Recruiting - Clinical trials for Mantle Cell Lymphoma

Tissue Collection for Biomarkers Determining Resistance to Ibrutinib

CLARITY
Start date: October 2014
Phase: N/A
Study type: Observational

Clinical validation of biomarkers determining resistance to BTK inhibition with Ibrutinib in Mantle Cell Lymphoma and Chronic Lymphocytic Leukaemia Stage 1.

NCT ID: NCT02081937 Recruiting - Clinical trials for Mantle Cell Lymphoma

CART-19 Immunotherapy in Mantle Cell Lymphoma

Start date: March 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Patients receive anti-CD19-CAR (coupled with CD137 and CD3 zeta signalling domains)vector-transduced autologous T cells over a period of 4 or 5 consecutive days in an escalating dose. After completion of study treatment, patients are followed intensively for 6 months, every 3 months for 2 years, and annually thereafter for 10 years.

NCT ID: NCT01962636 Recruiting - Multiple Myeloma Clinical Trials

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Start date: December 2016
Phase: N/A
Study type: Interventional

This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative regimen will consist of cyclophosphamide (CY), fludarabine (FLU) and fractionated total body irradiation (TBI).

NCT ID: NCT00946374 Recruiting - Clinical trials for Mantle-Cell Lymphoma

Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma

HD-MCL2003
Start date: July 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to improve the overall survival of Mantle-Cell-Lymphoma (MCL) by a new concept of treatment with primary curative intention consisting of six courses of immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (SCT) and HLA-identical allogenic SCT after a dose-reduced conditioning regimen of total body irradiation (TBI) with 2 Gy and Fludarabine in younger patients with primary Mantle-Cell-Lymphoma